HIV phenotypes - gaining importance as surrogate markers in AIDS
Inpharma Weekly1992Vol. &NA;(850), pp. 3–3
Related Papers
- → Evaluation of a surrogate marker: validity and efficiency(2012)6 cited
- → Surrogate Endpoints in Clinical Trials(1996)29 cited
- Reassessing the validity of surrogate markers of drug efficacy in the treatment of coronary artery disease.(2009)
- → Advanced topics in evidence-based urologic oncology: Surrogate endpoints(2011)5 cited
- → Acceptance of Surrogate Endpoints by HTA Agencies in Europe(2013)